Hypoxia-Inducible Protein 2 (HIG2), a novel diagnostic marker for renal cell carcinoma and potential target for molecular therapy

Cancer Research

Volumn 65, Issue 11, 2005, Pages 4817-4826

  Togashi, Akira ^a   Katagiri, Toyomasa ^a   Ashida, Shingo ^a,c   Fujioka, Tomoaki ^d   Maruyama, Osamu ^b   Wakumoto, Yoshiaki ^b   Sakamoto, Yoshiro ^b   Fujime, Makoto ^b   Kawachi, Yoshio ^b   Shuin, Taro ^c   Nakamura, Yusuke ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b JUNTENDO UNIVERSITY   (Japan)

^c KOCHI MEDICAL SCHOOL   (Japan)

^d IWATE MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; FRIZZLED PROTEIN; GENE PRODUCT; PROTEIN HYPOXIA INDUCIBLE PROTEIN 2; SMALL INTERFERING RNA; TUMOR MARKER; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL GROWTH; CHRONIC GLOMERULONEPHRITIS; CONTROLLED STUDY; CULTURE MEDIUM; DNA MICROARRAY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY CARCINOMA; ONCOGENE; PRIORITY JOURNAL; TUMOR GROWTH;

ANIMALS; CARCINOMA, RENAL CELL; CELL GROWTH PROCESSES; CERCOPITHECUS AETHIOPS; COS CELLS; HCT116 CELLS; HELA CELLS; HUMANS; KIDNEY NEOPLASMS; NEOPLASM PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; TRANSFECTION; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 21144438185     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-0120     Document Type: Article

References (23)

1. Ljungberg B, Alamdari FI, Rasmuson T, Roos G. Follow-up guidelines for nonmetastatic renal cell carcinoma based on the occurrence of metastases after radical nephrectomy. BJU Int 1999;84:405-11.
2. Levy DA, Slaton JW, Swanson DA, Dinney CP. Stage specific guidelines for surveillance after radical nephrectomy for local renal cell carcinoma. J Urol 1998;159:1163-7.
3. Takahashi M, Rhodes DR. Furge KA, et al. Gene expression profiling of clear cell renal cell carcinoma: gene identification and prognostic classification. Proc Natl Acad Sci U S A 2001;98:9754-9.
4. Young AN, Amin MB, Moreno CS, et al. Expression profiling of renal epithelial neoplasms. A method for tumor classification and discovery of diagnostic molecular markers. Am J Pathol 2001;158:1639-51.
5. Skubitz KM, Skubitz AP. Differential gene expression in renal-cell cancer. J Lab Clin Med 2002;140:52-64.
6. Takahashi M, Yang XJ, Sugimura J, et al. Molecular subclassification of kidney tumors and the discovery of new diagnostic markers. Oncogene 2003;22:6810-8.
7. Higgins JP, Shinghal R, Gill H, et al. Gene expression patterns in renal cell carcinoma assessed by complementary DNA microarray. Am J Pathol 2003;162:925-32.
8. Ono K, Tanaka T, Tsunoda T, et al. Identification by cDNA microarray of genes involved in ovarian carcinogenesis. Cancer Res 2000;60:5007-11.
9. Mintz PJ, Kim J, Do KA, et al. Fingerprinting the circulating repertoire of antibodies from cancer patients. Nat Biotechnol 2003;21:57-63.
10. Shimokawa T, Furukawa Y. Sakai M, et al. Involvement of the FGF18 gene in colorectal carcinogenesis, as a novel downstream target of the β-catenin/T- cell factor complex. Cancer Res 2003;63:6116-20.
11. Fujita M, Furukawa Y, Tsunoda T, et al. Up-regulation of the ectodermal-neural cortex 1 (ENC1) gene, a downstream target of the β-catenin/T-cell factor complex. in colorectal carcinomas. Cancer Res 2001; 61:7722-6.
12. Satoh S, Daigo Y, Furukawa Y, et al. AXINI mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXINI. Nat Genet 2000;24:245-50.
13. Denko N, Schindler C, Koong A, et al. Epigenetic regulation of gene expression in cervical cancer cells by the tumor microenvironment. Clin Cancer Res 2000;6: 480-7.
14. Saito-Hisaminato A, Katagiri T, Kakiuchi S, et al. Genome-wide profiling of gene expression in 29 normal human tissues with a cDNA microarray. DNA Res 2002; 9:35-45.
15. Nagayama S, Katagiri T, Tsunoda T, et al. Genome-wide analysis of gene expression in synovial sarcomas using a cDNA microarray. Cancer Res 2002; 62:5859-66.
16. Latif F, Tory K, Gnarra J, et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 1993;260:1317-20.
17. Corn PG, McDonald ER III, Herman JG, El-Deiry WS. Tat-binding protein-1, a component of the 26S proteasome, contributes to the E3 ubiquitin ligase function of the von Hippel-Lindau protein. Nat Genet 2003;35:229-37.
18. Semenza GL. Hypoxia-inducible factor 1: master regulator of O2 homeostasis. Curr Opin Genet Dev 1998;8: 588-94.
19. Zambrano NR, Lubensky IA, Merino MJ, Linehan WM, Walther MM. Histopathology and molecular genetics of renal tumors toward unification of a classification system. J Urol 1999;162:1246-58.
20. Bilim V, Kawasaki T, Katagiri A, et al. Altered expression of β-catenin in renal cell cancer and transitional cell cancer with the absence of β-catenin gene mutations. Clin Cancer Res 2000;6:460-6.
21. Kim YS, Kang YK, Kim JB, et al. β-Catenin expression and mutational analysis in renal cell carcinomas. Pathol Int 2000;50:725-30.
22. Zhu X, Kanai Y, Saito A, Kondo Y, Hirohashi S. Aberrant expression of β-catenin and mutation of exon 3 of the β-catenin gene in renal and urothelial carcinomas. Pathol Int 2000;50:945-52.
23. Michael A, Pandha HS. Renal-cell carcinoma: tumour markers, T-cell epitopes, and potential for new therapies. Lancet Oncol 2003;4:215-23.